This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
MARINA DEL REY, Calif.,
Dec. 31, 2012 /PRNewswire/ -- Prostate Oncology Specialists is pleased to announce that
Jeffrey Turner, MD has joined the prostate cancer specialist team. Dr. Turner is a board-certified internist and medical oncologist and will be specializing exclusively in prostate cancer with
Mark Scholz and
Richard Lam. Dr. Turner has been specializing in prostate cancer since 2009. He graduated cum laude from
USC. Thereafter, he worked in research at
UCLA studying infectious disease and molecular biology. He earned his medical degree in
Memorial University of Newfoundland and completed his internal medicine residency at the
University of British Columbia and fellowship in medical oncology at the
Medical University of South Carolina. Dr. Turner has published several articles on urologic cancers with an emphasis on prostate cancer. He is a sub-investigator of a number of ongoing prostate cancer clinical trials.
Mark Scholz, Medical Director of Prostate Oncology Specialists commented, "
Dr. Turner joins us during a time when the number of new prostate cancer treatments is exploding. He will add his expertise and knowledge to help patients make informed decisions. In 2012, we conducted clinical trials with Zytiga and Xtandi, agents that are now FDA approved. We are presently evaluating new agents such as Curstersin, XL-184 and Ipilimumab in combination with Provenge. We are happy to welcome a talented new member to the team who is familiar with all the many new treatment options for patients—this also includes Active Surveillance which is rapidly gaining acceptance as a viable treatment for prostate cancer."
Active Surveillance remains very popular given the alternative risk of permanent side-effects from surgery, radiation, or cryotherapy. Dr. Turner added,
"With the dramatic evolution of today's imaging techniques (including color Doppler ultrasound and MRI), Active Surveillance is best for men with Gleason 6, PSA<10, and clinical stage less than or equal to T2a. Due to the fact that men with Gleason 6 prostate cancer have an incredibly low risk of mortality, Active Surveillance should remain a strong alternative."
As skilled leaders in treating prostate cancer, our medical oncologists use PSA monitoring and color Doppler scanning to accurately monitor men on Active Surveillance. These techniques can detect early disease progression in men who may need to pursue treatment intervention.